
|Articles|April 8, 2019 (Updated: December 19, 2020)
Osimertinib Plus Savolitinib Shows Activity in EGFR-Mutant, MET-Amplified NSCLC
Author(s)Lecia V. Sequist, MD, MPH
Cancer Network spoke with Lecia V. Sequist, MD, MPH, about the TATTON study, which tested the combination of osimertinib and savolitinib in previously treated non–small-cell lung cancer patients.
Advertisement
Cancer Network spoke with Lecia V. Sequist, MD, MPH, about the TATTON study, which tested the combination of osimertinib and savolitinib in previously treated non–small-cell lung cancer patients.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Related Content
Advertisement




Evaluating the Cost-Effectiveness of Immunotherapy in Lung Cancers
Published: | Updated:

Optimizing the Use of Hypofractionated Radiotherapy in Lung Cancer Care
Published: | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
What Were The Key Prostate Cancer Abstracts at ASCO GU 2026?
2
FDA Grants Tentative Approval to PNT2003 for GEP-NETs
3
THP Yields Noninferior pCR vs TCbHP in HER2-Positive Early Breast Cancer
4
Evaluating CAR T-Cell Suitability and Pre Treatment Planning After Bispecific Exposure in High Risk Multiple Myeloma
5
















































